(UroToday.com) The 2025 European Society of Medical Oncology (ESMO) Annual Congress held in Berlin, Germany between October ...
In the phase 1 portion of the trial, two doses of gedatolisib were administered IV on an intermittent schedule (Days 1, 8, 15 ...
(UroToday.com) The 2025 European Society for Medical Oncology (ESMO) Annual Congress was host to a radioligand therapeutics ...
The 2025 ESMO annual meeting featured a prostate cancer session and a presentation by Dr. Alicia K. Morgans discussing ...
KLK2 protein is overexpressed in prostate cancer tissue compared to benign prostate tissue and has been associated with stage ...
At the ESMO 2025 annual meeting, Dr. Hansen and colleagues presented the first-in-human data of 212 Pb-ADVC001 in patients ...
Follow-up was done according to EAU guidelines. In 27 patients mIR-371 was evaluated preoperatively and correlated with ...
Specific to patients with muscle invasive bladder cancer, improvement in disease free survival was also observed with ...
The study investigators concluded that EV+P demonstrated activity in advanced urothelial carcinoma tumors with histologic ...
HER-2 targeted antibody-drug conjugate monotherapy has demonstrated efficacy in the post-chemotherapy setting for ...
A New Era in the Treatment of Muscle Invasive Bladder Cancer. Discussant of LBA2 - Perioperative (Periop) Enfortumab Vedotin ...
Dr. Ignacio Duran titled his discussion of abstracts 2595MO, 2600MO, 2610MO: Bringing any clarity into the non-clear or ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback